N-(2-Bromophenyl)-2-{[6-({[(2-bromophenyl)carbamoyl]methyl}sulfanyl)hexyl]sulfanyl}acetamide

Catalog No. :
ACWHLG213
CAS No. :
329778-03-2
Molecular Formula :
C22H26Br2N2O2S2
Molecular Weight :
574.40

IUPAC Name:2,2'-(hexane-1,6-diylbis(sulfanediyl))bis(N-(2-bromophenyl)acetamide)

N-(2-Bromophenyl)-2-{[6-({[(2-bromophenyl)carbamoyl]methyl}sulfanyl)hexyl]sulfanyl}acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$323.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(2-Bromophenyl)-2-{[6-({[(2-bromophenyl)carbamoyl]methyl}sulfanyl)hexyl]sulfanyl}acetamide
IUPAC Name2,2'-(hexane-1,6-diylbis(sulfanediyl))bis(N-(2-bromophenyl)acetamide)
MDL No.MFCD00955070
Molecular FormulaC22H26Br2N2O2S2
Molecular Weight574.40
SMILESO=C(NC1=CC=CC=C1Br)CSCCCCCCSCC(NC2=CC=CC=C2Br)=O
InChI KeyUVBGPLAZLWQNRZ-UHFFFAOYSA-N
Synonym2-[(6-([2-(2-BROMOANILINO)-2-OXOETHYL]SULFANYL)HEXYL)SULFANYL]-N-(2-BROMOPHENYL)ACETAMIDE;N-(2-bromophenyl)-2-{[6-({[(2-bromophenyl)carbamoyl]methyl}sulfanyl)hexyl]sulfanyl}acetamide;Acetamide, 2,2'-[1,6-hexanediylbis(thio)]bis[N-(2-bromophenyl)- (9CI);N-(2-BR-PH)-2-(6-((2-BR-PHENYLCARBAMOYL)-METHYLSULFANYL)-HEXYLSULFANYL)ACETAMIDE
CAS No.329778-03-2

Synthetic Route by SureRoute

1. ACWHLG213 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWHLG213 route product structure diagram
    ACWHLG213329778-03-2
Inquiry

2. ACWHLG213 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCGWL165 route compound structure diagram
    ACCGWL16594718-79-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWHLG213 route product structure diagram
    ACWHLG213329778-03-2
Inquiry

Comments (0)